68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours
- PMID: 31542317
- DOI: 10.1016/j.radonc.2019.09.003
68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours
Abstract
Purpose: [177Lu]DOTATATE prolongs progression free survival (PFS) in metastatic neuroendocrine tumours (NETs). However, objective response rate is low. This, coupled with long duration of therapy and expense suggest need for better selection. We aim to assess whether baseline [68Ga]DOTATATE-PET/CT parameters, and whether response assessment by PET accurately predicts clinical outcome to [177Lu]DOTATATE.
Experimental design: Retrospective study of patients receiving [177Lu]DOTATATE was conducted. Patients were followed 3-monthly until disease progression. Four [68Ga]DOTATATE-PET parameters (single lesion SUVmax, tumour to spleen and liver SUV ratios, and SUVmax-av using up to five target lesions in multiple organ sites) were determined at baseline and follow-up. The association between these PET parameters either at baseline, or any changes following treatment, and PET response criteria (PERCIST and modified PERCIST) to predict PFS were determined. Patients were followed 3-monthly until disease progression. Response was determined using RECIST 1.1. Baseline SSTR2 expression was assessed and compared with PET parameters.
Results: 55 patients with metastatic NETs were identified predominantly small bowel (N = 18) and pancreatic (N = 8) in origin. 16 were low grade, 15 intermediate and 3 high grade. Response to PRRT (N = 47): partial response (PR) 28%, stable disease (SD) 60% progressive disease (PD) 13%. Response to PRRT predicted PFS: PR 71.8 months (95%CI: not achieved), SD 29.1 months (95%CI: 15.2-43.1), and PD 9.7 months (95%CI: 0-21.02). Baseline, single lesion SUVmax predicted both response and PFS with SUV cut-off of 13.0 giving high sensitivity and specificity. Tumoural SUVmax correlated with SSTR2 expression, Spearman's rho - 0.69, p < 0.01.
Conclusions: Baseline single lesion SUVmax and SUVmax-av predicts response to [177Lu]DOTATATE. Objective response following PRRT defines a subset of patients with markedly improved PFSBaseline SUVmax 13.0 defines a threshold below which patients have poor response to PRRT and worse PFS. SUV threshold analysis should be taken forward into prospective studies.
Keywords: Neuroendocrine tumours; Peptide receptor radiotherapy; Response assessment; SUV(max); [(68)Ga]-DOTATATE.
Crown Copyright © 2019. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting.Br J Radiol. 2021 Jan 1;94(1117):20201041. doi: 10.1259/bjr.20201041. Epub 2020 Oct 29. Br J Radiol. 2021. PMID: 33095671 Free PMC article.
-
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.J Nucl Med. 2024 Feb 1;65(2):236-244. doi: 10.2967/jnumed.123.265987. J Nucl Med. 2024. PMID: 38164576 Clinical Trial.
-
Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE.Ann Nucl Med. 2024 Apr;38(4):296-304. doi: 10.1007/s12149-023-01899-w. Epub 2024 Jan 22. Ann Nucl Med. 2024. PMID: 38252228
-
Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.Eur Radiol. 2023 Oct;33(10):7089-7098. doi: 10.1007/s00330-023-09697-8. Epub 2023 May 6. Eur Radiol. 2023. PMID: 37148355 Review.
-
Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.Curr Radiopharm. 2019;12(2):126-134. doi: 10.2174/1874471012666190201164132. Curr Radiopharm. 2019. PMID: 30714538 Review.
Cited by
-
Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Curr Oncol Rep. 2024 May;26(5):538-550. doi: 10.1007/s11912-024-01526-5. Epub 2024 Apr 6. Curr Oncol Rep. 2024. PMID: 38581469 Free PMC article. Review.
-
Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.J Nucl Med. 2024 Feb 8;65(3):416-22. doi: 10.2967/jnumed.123.266601. Online ahead of print. J Nucl Med. 2024. PMID: 38331457 Free PMC article.
-
Prediction of 177Lu-DOTATATE Therapy Outcomes in Neuroendocrine Tumor Patients Using Semi-Automatic Tumor Delineation on 68Ga-DOTATATE PET/CT.Cancers (Basel). 2023 Dec 31;16(1):200. doi: 10.3390/cancers16010200. Cancers (Basel). 2023. PMID: 38201627 Free PMC article.
-
Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis.Quant Imaging Med Surg. 2023 Oct 1;13(10):6814-6826. doi: 10.21037/qims-23-477. Epub 2023 Aug 31. Quant Imaging Med Surg. 2023. PMID: 37869289 Free PMC article.
-
Molecular Imaging in Recurrent Prostate Cancer Presented as a Mixed Small Neuroendocrine Tumor/Acinar Adenocarcinoma.Nucl Med Mol Imaging. 2023 Aug;57(4):209-211. doi: 10.1007/s13139-023-00800-x. Epub 2023 Apr 5. Nucl Med Mol Imaging. 2023. PMID: 37483874
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous